Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim about severe acute hepatitis B exacerbations with discontinuation of BIKTARVY is directly supported by the supplied FDA label text (Sections 5.1 and 17), with no contradictions.
Category Scores
Accurate Statements
Severe acute exacerbations of hepatitis B may occur with discontinuation of BIKTARVY in patients with HIV-1 and HBV.
Supported by Warnings and Precautions (5.1) and Patient Counseling Information (17): label states severe acute exacerbations have been reported after discontinuation of FTC and/or TDF-containing products and may occur with discontinuation of BIKTARVY.
Unsupported Statements
Contradictions
Important Omissions
Close clinical and laboratory monitoring for at least several months after stopping BIKTARVY, and that anti-hepatitis B therapy may be warranted in appropriate patients.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The key safety warning is accurately stated and aligned to the label; however, monitoring/management details included in the label are omitted from the claim content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label’s specified monitoring duration and possible need for anti-hepatitis B therapy after discontinuation.
Suggested Improvement
When restating the warning, include that patients should be closely monitored with clinical and laboratory follow-up for at least several months after stopping, and that anti-HBV therapy may be warranted for appropriate patients (e.g., advanced liver disease/cirrhosis).